KROS vs VIR

Key Takeaways

• KROS and VIR are both clinical-stage biotechnology companies with no approved commercial products, but they pursue fundamentally different therapeutic areas and pipeline strategies.
• Keros Therapeutics posted a net income of $87 million in fiscal 2025 driven by a transformative Takeda licensing deal, while Vir Biotechnology reported a net loss of $438 million as it funds multiple Phase 3 registrational programs.
• Vir Biotechnology commands a market capitalization of approximately $1.48 billion — roughly seven times larger than Keros at $202 million — reflecting broader pipeline diversification across hepatitis delta and immuno-oncology.
• Both companies maintain cash runways into the first half of 2028, but Keros deployed an aggressive $375 million capital return program that reduced its cash reserves and share count substantially.
• KROS trades near the low end of its 52-week range at approximately $10.21, while VIR has posted a one-year gain of roughly 56% despite recent pullbacks to around $8.80.
• Analyst consensus ratings are positive for both stocks, but Vir's "Strong Buy" rating and 145% upside to its average price target reflect more visible near-term catalysts across its pipeline.

Introduction

In the high-risk, high-reward landscape of clinical-stage biotechnology, KROS (Keros Therapeutics) and VIR (Vir Biotechnology) represent two distinct investment propositions. Both companies operate without commercial-stage products, relying on partnership revenue, milestone payments, and cash reserves to fund research and development (R&D). Yet their pipelines, therapeutic focus areas, and recent financial trajectories diverge significantly. For investors evaluating relative performance and market positioning within the biotech sector, this head-to-head comparison provides a data-driven framework for understanding where each company stands in the current market cycle — and which one may present a more compelling risk-reward profile based on observable factors.

KROS Overview and Recent Performance

Keros Therapeutics is a clinical-stage biopharmaceutical company specializing in the transforming growth factor-beta (TGF-ß) family of proteins — master regulators of growth, repair, and maintenance across blood, bone, skeletal muscle, adipose, and heart tissue. The company's pipeline includes elritercept (KER-050), its most advanced candidate, partnered with Takeda Pharmaceuticals for the treatment of cytopenias in myelodysplastic syndromes (MDS) and myelofibrosis (MF). Its lead wholly owned program, rinvatercept (KER-065), targets Duchenne muscular dystrophy (DMD) with a Phase 2 trial expected to initiate in the second quarter of 2026.

The financial profile of KROS shifted dramatically in fiscal 2025. Total revenue surged to $244.1 million from just $3.6 million the prior year, almost entirely attributable to license revenue recognized under the Takeda agreement. This enabled Keros to report full-year net income of $87.0 million, a sharp turnaround from a $187.4 million net loss in 2024. However, the revenue composition is heavily one-time in nature — the bulk came from a $200 million upfront payment and a $10 million development milestone — and forward revenue visibility remains dependent on unpredictable milestone cadences. The company also executed a $375 million capital return program, repurchasing approximately 36% of outstanding shares and cutting shares outstanding to roughly 19.5 million. Cash and equivalents ended 2025 at $287.4 million, expected to fund operations into the first half of 2028.

In recent weeks, KROS has traded near the lower bounds of its 52-week range of $9.69 to $22.55, with the stock hovering around $10.21. The decline reflects lingering concerns about pipeline concentration risk following the December 2024 voluntary halt of the cibotercept (KER-012) Phase 2 TROPOS trial in pulmonary arterial hypertension (PAH) due to pericardial effusion adverse events — a development that erased roughly 73% of the company's market value in a single day and fundamentally reset investor expectations.

VIR Overview and Recent Performance

Vir Biotechnology is a clinical-stage immunology company that combines antibody discovery, T-cell engager platforms, and proprietary masking technologies to address serious infectious diseases and solid tumors. Its lead program targets chronic hepatitis delta (CHD), the most severe form of chronic viral hepatitis, using a combination of tobevibart (an investigational monoclonal antibody) and elebsiran (an investigational small interfering RNA, or siRNA). Phase 2 SOLSTICE data presented in early 2026 demonstrated that 88% of evaluable participants achieved undetectable hepatitis delta virus RNA at 96 weeks of treatment. The ECLIPSE Phase 3 registrational program is now fully underway, with topline data from ECLIPSE 1 expected in the fourth quarter of 2026.

On the oncology front, Vir's proprietary PRO-XTEN® dual-masked T-cell engager (TCE) platform has generated considerable attention. The company announced a global strategic collaboration with Astellas to advance VIR-5500, a PSMA-targeted TCE for metastatic castration-resistant prostate cancer (mCRPC), with updated Phase 1 data showing dose-dependent anti-tumor activity and a favorable safety profile. Additional masked TCE candidates — VIR-5818 targeting HER2 and VIR-5525 targeting EGFR (epidermal growth factor receptor) — are also progressing through early clinical evaluation.

Financially, VIR posted full-year 2025 revenue of $68.6 million and a net loss of $438.0 million, an improvement from a $522.0 million loss in 2024. The company ended 2025 with $781.6 million in cash, cash equivalents, and investments, and guided that its runway extends into the second quarter of 2028. In recent weeks, the stock has pulled back from its 52-week high of $11.66 to approximately $8.80, though it remains up roughly 56% on a trailing one-year basis. The pullback appears tied to broader biotech sector weakness and profit-taking following the Astellas collaboration announcement, rather than company-specific negative developments.

Trending AI Robots

For traders seeking to navigate the volatility inherent in clinical-stage biotech stocks like KROS and VIR, automated strategies can offer a systematic edge. Tickeron's Trending AI Robots page curates a select subset of the platform's hundreds of available AI trading bots — each designed with unique trading styles, strategies, timeframes, and risk parameters. Only those bots demonstrating the strongest adaptation to current market conditions earn placement in this curated section. The bots trade across thousands of tickers and span timeframes from ultra-short 5-minute and 15-minute agents to longer-duration 60-minute strategies. Top-performing bots in Tickeron's ecosystem have posted annualized returns ranging from 78% to over 290%, with some strategies achieving Sharpe ratios above 2.0 — a metric that measures risk-adjusted returns. Each bot displays transparent performance statistics including closed trade profit/loss, drawdown, and trade frequency. For traders and investors who want to complement their own research with AI-driven signals, exploring the Trending AI Robots page can offer a data-driven starting point for evaluating systematic trading approaches.

Head-to-Head Comparison

Business Model and Pipeline Breadth: Keros is highly concentrated around the TGF-ß pathway, with its lead asset elritercept now largely in Takeda's hands and its internal future tied heavily to rinvatercept in DMD. Vir Biotechnology, by contrast, operates across two major therapeutic pillars — CHD (with a registrational Phase 3 program) and immuno-oncology (with three clinical-stage masked TCEs and multiple preclinical candidates). Vir's pipeline diversification reduces single-asset binary risk relative to Keros, though it also means higher aggregate R&D spending.

Financial Positioning: Keros used its Takeda windfall to engineer a dramatic share count reduction and report GAAP (Generally Accepted Accounting Principles) profitability in 2025, but the sustainability of those results is questionable given the one-time license revenue composition. VIR continues to post substantial losses — $438 million in 2025 — but its $781.6 million cash position is more than 2.7 times larger than Keros's $287.4 million, providing a thicker cushion for clinical execution.

Risk Factors: Keros faces lingering reputational and pipeline risk from the cibotercept trial halt. The stock's price-to-book (P/B) ratio of approximately 0.69 indicates the market is pricing in material uncertainty about its remaining pipeline prospects. Vir's risks center on clinical trial execution — the ECLIPSE program must deliver positive data to validate the CHD thesis — and competitive dynamics in both hepatitis and oncology.

Market Sentiment and Momentum: VIR's one-year gain of approximately 56% and its "Strong Buy" consensus from 10 analysts signal robust institutional confidence, supported by tangible catalysts including the Astellas deal and upcoming ECLIPSE data readouts. KROS trades near 52-week lows, with a "Buy" consensus from 9 analysts and a price target implying over 110% upside — a setup that suggests deep-value appeal but also reflects the market's skepticism about near-term catalysts.

Sector and Volatility Profile: VIR's beta of 1.62 indicates higher sensitivity to market swings than KROS's beta of approximately 0.97. Traders seeking lower correlation to broad market moves may find KROS's lower beta appealing, though this must be weighed against its higher stock-specific risk.

Tickeron AI Verdict

Based on observable factors including trend consistency, catalyst visibility, pipeline diversification, and relative market positioning, Tickeron's AI analytical framework would likely favor VIR over KROS in the current environment. Vir Biotechnology presents a more balanced risk profile: a registrational Phase 3 program with data expected within months, a validated partnership with a major pharmaceutical company in Astellas, compelling mid-stage clinical data in CHD, and a cash runway that comfortably supports operations through the critical catalyst window. The stock's ability to sustain a positive one-year return despite ongoing losses suggests the market is rewarding its execution and pipeline momentum. Keros Therapeutics, while trading at a statistically cheap valuation on a book-value basis, faces greater uncertainty around its wholly owned pipeline assets and must demonstrate that its post-Takeda strategy can generate sustainable value beyond a one-time licensing windfall. This assessment is probabilistic in nature and reflects current observable data rather than a definitive prediction of future outcomes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations